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Abstract
Background: Drug resistant tuberculosis (TB) is increasing in prevalence worldwide. Treatment failure and relapse is
known to be high for patients with isoniazid resistant TB treated with standard first line regimens. However, risk
factors for unfavourable outcomes and the optimal treatment regimen for isoniazid resistant TB are unknown. This
cohort study was conducted when Vietnam used the eight month first line treatment regimen and examined risk
factors for failure/relapse among patients with isoniazid resistant TB.
Methods: Between December 2008 and June 2011 2090 consecutive HIV-negative adults (≥18 years of age) with
new smear positive pulmonary TB presenting at participating district TB units in Ho Chi Minh City were recruited.
Participants with isoniazid resistant TB identified by Microscopic Observation Drug Susceptibility (MODS) had
extended follow-up for 2 years with mycobacterial culture to test for relapse. MGIT drug susceptibility testing
confirmed 239 participants with isoniazid resistant, rifampicin susceptible TB. Bacterial and demographic factors
were analysed for association with treatment failure and relapse.
Results: Using only routine programmatic sputum smear microscopy for assessment, (months 2, 5 and 8) 30/239 (12.
6%) had an unfavourable outcome by WHO criteria. Thirty-nine patients were additionally detected with unfavourable
outcomes during 2 year follow up, giving a total of 69/239 (28.9%) of isoniazid (INH) resistant cases with unfavourable
outcome by 2 years of follow-up. Beijing lineage was the only factor significantly associated with unfavourable
outcome among INH-resistant TB cases during 2 years of follow-up. (adjusted OR = 3.16 [1.54–6.47], P = 0.002).
Conclusion: One third of isoniazid resistant TB cases suffered failure/relapse within 2 years under the old eight
month regimen. Over half of these cases were not identified by standard WHO recommended treatment monitoring.
Intensified research on early identification and optimal regimens for isoniazid resistant TB is needed. Infection with
Beijing genotype of TB is a significant risk factor for bacterial persistence on treatment resulting in failure/relapse within
2 years. The underlying mechanism of increased tolerance for standard drug regimens in Beijing genotype strains
remains unknown.
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Background
Drug resistance in Mycobacterium tuberculosis (M.tuber-
culosis) is increasing worldwide and represents a major
challenge to global TB control efforts. In 2015, there
were 10.4 million new tuberculosis infections and 1.4
million deaths [1]. According to the World Health
Organization (WHO), 17% of strains are now resistant
to one or more of the major first line drugs [2]. Six per-
cent of new TB cases and 20% of retreatment cases are
multi-drug resistant (MDR TB) [2]. Multidrug resistant
TB (MDR TB) is defined as resistance to at least isonia-
zid and rifampicin, the two most effective drugs in anti-
tuberculous regimens. MDR TB must be treated with
second-line drug regimens which are longer in duration,
highly toxic, less potent and more expensive.
Rifampicin mono-resistance is rare and resistance to
isoniazid is therefore the key precursor in the generation
of MDR TB strains yet has received limited research at-
tention. Ten percent of new TB cases and one third of
retreatment cases globally are resistant to INH [2]. It is
known from meta-analysis of trial data that treatment
failure and relapse rates are higher among patients with
undiagnosed INH resistance, yet the majority of these
patients are still successfully treated using standard regi-
mens [3–7]. The determinants of failure and relapse in
those with INH resistance who fail despite good adher-
ence to standard therapy are not well understood.
In Vietnam, as in most high burden settings, full drug
resistance testing is only carried out for failure or
retreatment cases and therefore isoniazid resistance is
rarely detected in new TB cases. However, high treat-
ment failure rates in isoniazid resistant TB cases may be
fuelling the rise in MDR TB.
WHO has recommended that ethambutol (EMB) is
added to the continuation phase for all new patients in
countries with ‘high’ isoniazid resistance [8]. There is
limited evidence for the efficacy of this regimen and the
ocular toxicity of ethambutol will lead to cases of blind-
ness in unnecessarily treated patients with drug-sensitive
tuberculosis [9–13].
The study reported here aimed to determine [1] the
proportion of failure/relapse in isoniazid resistant cases
which is not captured by standard WHO monitoring [2]
if bacterial factors can be used to predict those at high-
est risk of failure/relapse among those with isoniazid re-
sistant tuberculosis and determine which patients would
most benefit from modified regimens.
We assessed bacterial lineage, resistance mutation, iso-
niazid minimum inhibitory concentration (MIC), and
additional drug resistance in 239 patients with INH re-
sistant tuberculosis identified among a cohort of 2091
new smear positive pulmonary TB patients. INH resist-
ant TB included all isolates resistant to INH but suscep-
tible to rifampicin (ie. Not MDR TB). Patients with INH
resistant TB were followed for 2 years to determine
the rate of relapse/failure which is not detected by
standard WHO criteria for TB treatment outcome
classification.
Methods
Ethics
The study was approved by the Institutional Research
Board of Pham Ngoc Thach Hospital as the supervisory
institution of the district TB Units (DTUs) in southern
Vietnam, Ho Chi Minh City Health Services and the
Oxford University Tropical Research Ethics Committee
(Oxtrec 030–07). Written informed consent was ob-
tained from all patients prior to screening for INH
susceptibility and, if resistant by MODS testing, a second
written informed consent was obtained for enrolment
into the INH study.
Recruitment
HIV uninfected adult (≥18 years of age) patients with
new smear positive pulmonary tuberculosis presenting at
participating DTUs in Ho Chi Minh City were invited to
participate. From December 2008 four DTUs (districts 4,
6, Binh Thanh and Phu Nhuan) and the out-patient
department at Pham Ngoc Thach Hospital recruited
patients. In October 2009, a further 4 DTUs joined the
study (district 1, 3, 8 and Tan Binh). District 3 was
withdrawn from the study due to low recruitment (9 pa-
tients) in early 2010. A map of participating DTU sites is
shown in Fig. 1. The study completed recruitment at all
sites in June 2011.
If written informed consent was given for INH sus-
ceptibility screening, a sputum sample was sent to the
microbiology laboratory at Pham Ngoc Thach hospital
for MODS testing. Patients with isoniazid susceptible
tuberculosis by MODS were then followed up accord-
ing to routine DTU practice using standard WHO
outcomes (smear at 2, 5 and 8 months) and no fur-
ther testing was conducted for the study. All patients
with isoniazid resistant TB by MODS screening were
invited to participate in the INH study, with more
detailed follow-up and testing. A second written in-
formed consent was obtained for recruitment to the
INH study.
Inclusion criteria for screening were a negative HIV
test, written informed consent, a positive sputum smear,
no previous TB treatment, ≥18 years of age, not preg-
nant or planning to receive DOTS outside the participat-
ing study centres. Patients were eligible for inclusion in
the extended INH study if they met the above criteria,
gave written informed consent to the extended INH
study and were infected by a strain resistant to INH on
MODS screening.
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Treatment
Patients received treatment determined by the treating
physician and usually in accordance with Vietnamese
National TB Program (NTP) guidelines, which at the
time of the study did not include any change in treat-
ment for INH resistant TB unless the patient remained
smear positive at 5 months. In accordance with NTP
policy, patients smear positive at 5 months are classified
as a treatment failure, tested for MDR TB and started on
the retreatment regimen.
When the study commenced the standard regimen
used in Vietnam was streptomycin (STR/S), rifampicin
(RIF/R), INH (H) and pyrazinamide (PZA/Z) for the first
two months (intensive phase) followed by 6 months with
INH and EMB (continuation phase; 2SHRZ/6HE). In
October 2009 the NTP replaced STR with EMB
(2RHZE/6HE) as the first stage in a phased transition to
the six month regimen (2RHZE/4HR) regimen. This en-
abled us to retrospectively compare failure and relapse
rates between the two regimens (2SHRZ/6HE and
2RHZE/6HE) for patients with INH resistant TB but
was not part of the original study design.
MODS was not accepted as a diagnostic assay for drug
resistance within the NTP at the time of the study
therefore patients with MDR TB diagnosed by MODS
were referred to the NTP MDR treatment programme
for confirmatory testing (using line-probe assay) and
treatment according to standard NTP practice.
Follow-up
All patients in the screening and INH study were
followed up according to WHO guidelines with sputum
smear evaluation at 2, 5 and 8 months (treatment com-
pletion). A positive sputum smear at month 5 or later
was classified as a retreatment case and further managed
according to standard NTP practice. In addition, pa-
tients in the extended INH study were further evaluated
for symptoms and sputum culture at month 8, 12, 18
and 24. A positive smear or culture at month 5 or later
was classified as a failure/relapse case. MDR patient out-
comes were not followed-up.
MODS testing
Drug susceptibility testing by direct MODS was per-
formed according to the standard protocol for isoniazid
and rifampicin [14]. Between December 2008 and 31
August 2010 the critical concentration for isoniazid was
0.4μg/ml. In 2010 the international recommended critical
Fig. 1 Map of geographical location of eight District TB Units in central Ho Chi Minh City participating in the study
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concentration changed to 0.1μg/ml following a meta-
analysis by Minion et al. showing an increase in sensitivity
compared to Lowenstein-Jensen (LJ) drug susceptibility
testing (DST; 97.7% vs. 90.0%) [15] and we therefore
adopted this change from 1st September 2010 until the
end of the study (June 2011) [15].
Bactec MGIT
Phenotypic drug susceptibility testing for STR, INH, RIF
and EMB was performed for all isolates at completion of
the study using Bactec MGIT SIRE at the OUCRU la-
boratory. MGIT DST results were used as the gold
standard for confirmation of INH resistance in further
analysis.
Isoniazid MIC
INH antibiotic powder (Sigma, Germany) was used
for determination of the INH MIC concentration at
0.2 μg/ml, 1 μg/ml, 2 μg/ml, 4 μg/ml, 8 μg/ml and
16 μg/ml using the 1% proportion method on LJ
media.
Genotyping
DNA extraction was performed using the CTAB (cetyl
trimethylammonium bromide)/chloroform method [16].
Isolate lineage was determined by Large Sequence Poly-
morphism (LSP) typing for RD105, RD239 and pks 15/1,
as previously described [17]. Isolates were categorised into
one of 3 major lineages; Euro-American, East-Asian
or Indo-Oceanic. Any isolates failing to generate PCR
products for LSP typing were typed and classified by
spoligotyping using the standard methods [18] and
the international spoligotyping database [19].
Statistical analysis
Treatment outcomes were categorized as favourable
(cured and treatment completed) or unfavourable (death,
treatment failed) according to WHO classifications. For
INH resistant TB cases unfavourable outcomes included
positive culture at month 5 or later.
INH-R TB was any Mtb resistant to isoniazid but sus-
ceptible to rifampicin (not MDR). Isolates in the INH-R
cohort therefore included both INH monoresistant
strains and strains resistant to INH and additionally
resistant to streptomycin and/or ethambutol.
Multivariate logistic regression was used to identify
variables associated with unfavourable outcome (death
or treatment failure). A P-value of ≤0.05 was considered
significant. All statistical analysis was done on Stata
version 10 (Statacorp, USA).
Results
Treatment outcomes in screening patients
One patient Case Report Form (CRF) was irretrievable
and therefore 2090 new pulmonary TB patients were eval-
uated by sputum smear microscopy after 5 and 8 months
according to WHO guidelines followed by Vietnam
NTP. The majority of patients (95.1%, n = 1987/2090)
received the daily regimen according to Vietnamese
NTP guidelines.
In total, 547 patients received 2SRHZ/6HE and 1440
patients received 2RHZE/6HE. The remaining 103 pa-
tients received alternative individualized regimens, such
as 2SRHZ/RHZ/5HE, 2SRHZE/RHZE/5RHE, 3RHZE/
5HE, 3RHZE/3RH, 2SRHZ/4RH and 2RHZE/4RH.
Patients treated at Pham Ngoc Thach hospital out-
patient department were much more likely to receive in-
dividualized treatment regimens than those treated at
the district TB units. Of those receiving individualized
regimens, 95/103 (92.2%) were treated at Pham Ngoc
Thach hospital out-patient department.
Overall, 1858 (88.9%) patients were cured and 6 (0.3%)
patients were classified as ‘treatment completed’, there-
fore, 1864 patients (89.2%) were classified as having a
favorable outcome. 16 patients died (0.8%), 121 (5.8%)
failed treatment, 82 were lost to follow up (3.9%) and 7
(0.3%) were not evaluated. Therefore, a total of 226/2090
patients (10.8%) were classified as having an unfavour-
able outcome by WHO criteria.
Comparison of treatment outcomes of two standardized
treatment regimens (2SRHZ/6HE and 2RHZE/6HE)
The crude odds ratio (OR) for unfavourable outcome was
0.94 [95% CI 0.65–1.35, P = 0.723] for patients receiving
2RHZE/6HE compared to those receiving 2SRHZ/6HE.
Adjusting for resistance to INH or MDR by MGIT DST
did not substantially change the OR: adjusted OR = 1.09
[95% CI 0.71–1.66], P = 0.703.
MODS screening
MODS cultures were positive for mycobacteria growth
in 1804 cases. Of these, 1407 cases (67.3%) were suscep-
tible to both RIF and INH, 324 cases (15.5%) were resist-
ant to INH and susceptible to RIF, 5 cases (0.2%) were
susceptible to INH and resistant to RIF, 68 cases (3.3%)
were resistant to both INH and RIF (MDR). There were
202 cases (9.7%) which had a negative MODS culture
and 85 cases (4.1%) that were indeterminate. The inde-
terminate category included isolates for which there was
a negative result in the MODS control well and/or con-
tamination of the control or sample well.
The change of INH critical concentration, from
0.4 μg/ml to 0.1 μg/ml, increased the percentage of iso-
lates determined as INH resistant by MODS from 17.4%
to 21.2%.
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The percentage of isolates resistant to INH by MODS
which were confirmed by MGIT DST increased signifi-
cantly following the concentration change; 88.3% (n = 197/
223) for 0.4 μg/ml and 98.4% (n = 120/122) for 0.1 μg/ml
(P = 0.0007).
Overall, there were 392 cases with INH resistance by
MODS (324 cases which were rifampicin susceptible and
68 cases which were MDR). 50 (12.6%) cases declined to
participate in the INH study. Therefore, 274 cases of
INH resistant TB were eligible to enter the INH study.
MGIT DST results
Further analysis of INH-resistant TB and MDR TB cases
was based upon those with available MGIT DST as the
gold standard (n = 1710, Table 1). Treatment outcome
analysis included only those receiving standardised treat-
ment regimens (n = 1623).
Risk factors for INH resistant TB and MDR TB
Demographic risk factors for INH-resistant and MDR
TB are shown in Table 2. Analysis of the association be-
tween bacterial lineage and INH resistant TB or MDR
TB is shown in Table 3.
Association between bacterial lineage and INH resistance
mutations
Among 457 isolates resistant to INH by MGIT, Beijing
lineage was significantly associated with katG315 muta-
tion among INH resistant isolates, (OR = 2.10 [95% CI
1.41–3.13], P = < 0.0001), while Indo-Oceanic strains
were significantly less likely to have a katG315 mutation
(OR = 0.34 [95%CI 0.16–0.70], P = 0.003). No lineage
showed an association with inhA − 15 promoter muta-
tion. Indo -Oceanic strains were significantly more likely
to be wild type, carrying neither a katG 315 nor an inhA
− 15 mutation.
Treatment outcomes among INH resistant TB cases
239 patients in the extended INH study had confirmed
INH resistant, RIF susceptible isolates by MGIT DST, re-
ceived a standardised regimen and were therefore
analysed for risk factors associated with unfavourable
outcome. Using only routine programmatic sputum
smear microscopy for assessment, 30/239 (12.6%) had
an unfavourable outcome by WHO criteria. Thirty-nine
patients were additionally detected with unfavourable
outcomes during 2 year follow up, giving a total of 69/
239 (28.9%) of INH resistant cases with unfavourable
outcome by 2 years of follow-up.
Level of INH resistance (MIC)
LJ MIC results were available for 214/239 isolates.
Among 239 isolates MIC for INH resistance were
0.2 μg/ml: 26, 1 μg/ml n = 81, 2 μg/ml n = 94, 4 μg/ml
n = 8, 8 μg/ml n = 2 and 16 μg/ml n = 3.
MIC to INH was categorized into high (≥ 1 μg/ml)
and low (< 1 μg/ml) for further analysis. Treatment out-
comes (determined using smear and culture results)
were evaluated by INH MIC level for 239 cases. There
was no association between high MIC and unfavourable
outcome (OR = 1.15 [95%CI 0.46–2.89], P = 0.764) or
bacterial lineage (ANOVA, P = 0.289).
Bacterial factors associated with unfavourable treatment
outcome among INH resistant cases
Analysis of bacterial factors associated with treatment
failure in isoniazid resistant TB cases is shown in Table 4.
Beijing lineage was the only factor significantly associ-
ated with unfavourable outcome during 2 years of
follow-up. (adjusted OR = 3.16 [1.54–6.47], P = 0.002.
Discussion
Approximately one third (28.9%) of INH-resistant TB
cases which were susceptible to rifampicin had failed or
relapsed treatment within two years of starting treat-
ment. Importantly, only 12.6% (n = 30/239) were classi-
fied as unfavourable outcome using WHO criteria of
sputum smear evaluation at 5 and 8 months and so the
majority of these cases would have been classified as
‘cured’ and received no further evaluation under stand-
ard practice. Overall, the cohort of 2090 patients had
treatment outcomes within the WHO targets for pro-
grammatic delivery which masked an unacceptably high
failure/relapse rate among INH-resistant TB cases. It is
Table 1 Drug susceptibility results by MGIT testing of 1710
isolates
Resistance pattern Number (%)
Fully susceptible 942
Streptomycin 285
Streptomycin, isoniazid 278
Izoniazid 94
Streptomycin, isoniazid, rifampicin, ethambutol 34
Streptomycin, isoniazid, rifampicin 33
rifampicin 7
ethambutol 2
Rifampicin, ethambutol 2
Isoniazid, ethambutol 4
Streptomycin, ethambutol 8
Streptomycin, rifampicin 6
Streptomycin, rifampicin, ethambutol 1
Streptomycin, isoniazid, ethambutol 12
Izoniazid, rifampicin 2
Total 1710
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possible that this undetected high relapse/failure is at
least partly responsible for the relatively slow decline in
TB incidence in Vietnam despite a comprehensive NTP
delivering DOTS and exceeding WHO targets for over
ten years. The addition of culture to evaluation detected
46 (19.2%) failures by 8 months, and a total of 69
(28.9%) cases by two years of follow-up. The regimens
used by the Vietnamese NTP at the time of this study
were inadequate for INH resistant TB and this is dem-
onstrated by the high rate of unfavourable outcomes in
this cohort. The regimen has now been changed in line
with revised WHO recommendations in areas of high
INH resistance to 2HRZE/4HRE [8]. However, there is
no existing evaluation of this regimen and the study re-
ported here raises the concern that current routine pro-
grammatic outcome surveillance may be inadequate to
detect failure/relapse in patients with INH resistant TB.
The East Asian/Beijing lineage was confirmed to be as-
sociated with MDR TB and INH resistant TB in Ho Chi
Minh City [17, 20–23]. This lineage was also shown to
be associated with treatment failure in INH resistant
cases. The reasons for this association with treatment
failure are not clear and require further research of the
pharmacodynamics associated with bacterial lineage to
Table 2 Demographic risk factors for MDR and INH resistant TB
MDR TB INH Resistant TB
OR 95% CI P-value OR 95% CI P-value
Male sex 1.00 0.54–1.85 0.993 1.05 0.80–1.38 0.710
Kinh ethnicity 1.10 0.34–3.59 0.870 1.35 0.78–2.35 0.282
Age category
1: 18–25 years Baseline
2: 26–35 years 2.98 1.26–7.03 0.013 1.11 0.77–1.59 0.584
3: 36–45 years 1.38 0.54–3.55 0.499 1.07 0.75–1.53 0.715
4: 46–55 years- 1.26 0.47–3.33 0.648 0.79 0.54–1.16 0.229
5: ≥56 years 0.74 0.19–2.89 0.665 0.77 0.48–1.21 0.255
District
Pham Ngoc Thach Baseline
Phu Nhuan 1.06 0.28–4.06 0.936 0.94 0.53–1.68 0.838
District 6 0.81 0.21–3.03 0.751 0.82 0.47–1.43 0.492
District 4 0.81 0.16–4.11 0.803 1.18 0.63–2.25 0.598
Binh Thanh 1.76 0.48–6.44 0.393 1.39 0.79–2.46 0.259
District 1 1.97 0.53–7.33 0.309 1.33 0.68–2.53 0.348
District 8 1.42 0.37–5.45 0.611 0.82 0.44–1.50 0.511
Tan Binh 0.60 0.12–3.02 0.535 0.76 0.40–1.45 0.405
Table 3 Association between drug resistance and bacterial lineage
Lineagea Drug resistance pattern Crude OR 95% CI P-value Adjusted ORb 95% CI P-value
Beijing n = 1017
INH resistant 1.45 1.15–1.81 < 0.001 1.44 1.15–1.81 0.002
MDR 2.59 1.44–4.63 0.001 2.54 1.42–4.57 0.002
Indo-Oceanic n = 406
INH resistant 0.63 0.49–0.83 < 0.001 0.63 0.48–0.83 0.001
MDR 0.37 0.17–0.78 0.009 0.37 0.18–0.79 0.010
Euro-American n = 181
INH resistant 0.88 0.62–1.25 0.477 0.89 0.62–1.26 0.504
MDR 0.36 0.11–1.17 0.091 0.37 0.11–1.19 0.094
aComparison for each lineage against all other strains. Lineage was indeterminate (mixed lineage, failed PCR or DNA not available) for 106/1710 (6.2%) strains
bAdjusted for young age (< 35 years of age) and sex
Statistically significant findings are highlighted in bold
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unravel the complexities of bacterial persistence during
treatment. Understanding of persistor mechanisms in
M.tuberculosis are thought to be the key to shortened
treatment regimens after the failure of three novel short
regimens containing fluoroquinolones for drug sensitive
TB in 2014 (OFLOTUB (NCT00216385), REMOX TB
(NCT00864383) and RIFAQUIN (ISRCTN44153044)
studies) [24–26].
Importantly the MIC to INH was not a risk factor for
treatment failure, suggesting the current critical concen-
tration 0.2 μg/ml for resistance is appropriate to define
clinical resistance with current INH dosages. Similarly,
despite reported associations of katG315 mutation with
higher MIC than inhA -15 [27–30], the mutation confer-
ring resistance could not be used to determine those at
high risk of treatment failure/relapse.
This study has several limitations in addition to the
outdated regimen assessed. Due to financial constraints,
there was no culture follow-up in the drug-susceptible
arm and therefore we were unable to compare the rates
of unfavourable outcome detected by enhanced evalu-
ation in INH susceptible TB cases. The 30-month report
of the landmark clinical trial ‘study A’ conducted by the
International Union against tuberculosis and Lung dis-
eases (IUATLD) showed an unfavourable outcome rate
of 10% for fully susceptibe TB at 30 months using the 8-
month regimen [31].
We did not determine if isolates from culture positive
cases post-treatment were due to relapse or reinfection,
beyond broad LSP typing, which is not sufficiently dis-
criminatory to confirm relapse. However, the contribu-
tion of reinfection is likely to be small as HCMC is not
an intensive transmission area and the annual infection
risk is low. There is a possibility that cases were rein-
fected from an untreated original household source, but
this would not in any case be detected by genotyping as
the genotypes would be identical to the original infection
event.
Changes in both the treatment regimen and MODS
INH critical concentration were made during the
study. Although outcome did not vary by treatment
regimen, the change in MODS concentration resulted
in an increased proportion of INH resistance detected
in the second part of the study and therefore recruited
into the intensive follow-up arm. We used MGIT DST
to confirm susceptibility in analysed INH-resistant
cases.
Conclusions
Overall, these data confirm that the East Asian/Beijing
lineage is associated with treatment failure in Vietnam.
The data showing a third of those with INH resistant
TB had unfavourable outcomes, the majority of which
were not detected by standard WHO follow-up, sug-
gest a rigorous evaluation of the new programmatic
regimen (2HRZE/6HE) for areas with high INH-
resistance is required. This should include symptom
evaluation and mycobacterial culture where indicated
up to 2 years to determine the true relapse and failure
rate of the regimen in cases of INH resistance. Cost-
effective solutions to early detection of INH resistant
TB are a research priority, as are randomised con-
trolled trials of alternative regimens for treatment of
INH-resistant TB.
Table 4 Analysis of bacterial risk factors associated with unfavourable outcome during 2-year follow-up in 239 INH-resistant TB cases
Risk factor Crude OR 95%CI P-value Adjusted ORa 95% CI P-value
Age < 35 years (n = 97) 0.77 0.43–1.38 0.383 0.71 0.39–1.30 0.267
Male sex (n = 177) 0.80 0.43–1.50 0.494 0.82 0.43–1.56 0.542
Ethambutol resistance (n = 7) 0.99 0.19–5.20 0.986 0.95 0.17–5.16 0.952
Streptomycin resistance (n = 185) 0.68 0.36–1.30 0.246 0.53 0.27–1.06 0.074
Treatment with streptomycin (n = 63) 1.21 0.65–2.25 0.558 1.28 0.67–2.45 0.449
INH MIC > 1 μg/ml (n = 107) 1.15 0.46–2.89 0.558 1.33 0.52–3.40 0.557
Resistance mutation
KatG 315 (n = 173 0.90 0.47–1.71 0.738 0.91 0.46–1.79 0.775
InhA −15 (n = 18) 0.48 0.13–1.72 0.262 0.41 0.11–1.50 0.178
Wild-type (n = 49) 1.53 0.75–3.10 0.243 1.69 0.79–3.64 0.177
Lineageb
Beijing (n = 163) 2.82 1.41–5.66 0.003 3.16 1.54–6.47 0.002
Euro-American (n = 31) 0.55 0.21–1.40 0.210 0.50 0.49–1.31 0.159
Indo-Oceanic (n = 30) 0.58 0.22–1.48 0.250 0.54 0.21–1.40 0.204
aadjusted for resistance to streptomycin and ethambutol
b6 isolates had an unclassified lineage
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